Introduction to Trispecific CAR T Therapy

Trispecific CAR T therapy represents a monumental advancement in the rapidly evolving landscape of cellular immunotherapy. Traditionally, CD19-directed chimeric antigen receptor (CAR) T cells have transformed the clinical management of relapsed or refractory B-cell malignancies. However, many patients eventually experience disease recurrence, creating a significant therapeutic challenge. This treatment failure often stems from the loss of the CD19 antigen or insufficient coverage of the tumor's surface markers. Consequently, researchers have turned their attention to multi-specific constructs to improve durability. The first-in-human phase I trial led by Vasu S and colleagues recently evaluated a novel trispecific CAR T cell product. This construct targets three distinct antigens simultaneously: CD19, CD20, and CD22. By expanding the breadth of tumor recognition, this therapy aims to prevent the "escape" of malignant cells that lack a single target. Furthermore, the inclusion of an OX40 co-stimulatory domain and the implementation of point-of-care manufacturing distinguish this approach from current commercial alternatives. This article explores the safety, manufacturing feasibility, and clinical outcomes of this pioneering trial.

The Mechanics of Triple Antigen Targeting

The design of a trispecific CAR is fundamentally complex yet logically sound for treating heterogeneous tumors. B-cell malignancies are inherently diverse, meaning different cells within the same tumor may express different surface proteins. Therefore, targeting CD19 alone creates a selective pressure that potentially allows CD19-negative clones to proliferate unchecked. To mitigate this risk, the trispecific CAR T therapy construct incorporates binding domains for CD19, CD20, and CD22. Preclinical studies initially demonstrated that this three-pronged approach provides potent, antigen-specific cytotoxicity. In both in vitro and in vivo models of lymphoma, these engineered cells successfully eradicated tumors that would have otherwise escaped single-antigen CARs. Notably, the simultaneous targeting of multiple antigens ensures that the immune system remains effective even if the tumor attempts to downregulate specific markers. Additionally, the researchers utilized a specific duoCAR architecture to co-express these domains efficiently. This structural innovation ensures high transduction efficiency and stable expression across the engineered T-cell population, providing a robust defense against common resistance mechanisms.

Advantages of OX40 Co-Stimulatory Domains

A crucial component of this trispecific CAR T therapy is the OX40 (CD134) co-stimulatory domain. Most commercial products currently utilize either 4-1BB or CD28 domains to provide the necessary secondary signals for T-cell activation. However, OX40 offers unique advantages in the context of cellular persistence and metabolic fitness. Specifically, OX40 signaling enhances the survival of effector T cells and promotes the formation of vital memory T cell subsets. This is particularly important because the lack of long-term persistence is a frequent cause of relapse in conventional CAR T therapy. Furthermore, the OX40 domain appears to reduce T-cell exhaustion, allowing the cells to remain functional in the immunosuppressive tumor microenvironment for longer periods. Consequently, the researchers observed durable remissions in lymphoma patients during the phase I trial. While 4-1BB is known for its safety and CD28 for its rapid expansion, OX40 may provide a balanced profile that optimizes both cytotoxicity and longevity. Thus, the integration of OX40 marks a strategic shift in CAR design aimed at improving the overall quality of the T-cell product.

Point-of-Care Manufacturing: A Seven-Day Revolution

The manufacturing process used in this trial represents a significant shift toward decentralization and therapeutic efficiency. Traditional CAR T production requires shipping patient cells to a central facility, which often results in a vein-to-vein time of several weeks. In contrast, this study utilized point-of-care manufacturing at the hospital site. By leveraging automated systems like the CliniMACS Prodigy, the team achieved a median vein-to-vein time of just seven days. This rapid turnaround is essential for patients with aggressive, fast-growing malignancies who cannot afford long delays. Moreover, the use of "fresh" cell infusions—infusing the cells shortly after they are manufactured—may preserve their stem-like memory phenotype. These stem-like cells are generally more effective at expanding and persisting within the patient compared to heavily manipulated or frozen products. Additionally, local manufacturing reduces the logistical burden and high costs associated with cryopreservation and international shipping. Therefore, this point-of-care model could significantly improve access to advanced immunotherapies, especially in regions with developing healthcare infrastructure where centralized logistics are challenging.

Safety Profiles and the Absence of Severe Neurotoxicity

Safety remains a paramount concern for any first-in-human trial involving such potent immunotherapies. Conventional CAR T treatments are frequently associated with severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). However, the results from this trispecific CAR T therapy trial were remarkably encouraging. Among the sixteen patients who received infusions at doses ranging from 0.5 to 2×10⁶ cells/kg, no cases of severe CRS or neurotoxicity occurred. This favorable safety profile is likely due to several factors, including the precise dosing and the specific co-stimulatory signals provided by the OX40 domain. Furthermore, the point-of-care manufacturing process might yield a more "fit" T-cell product that expands in a controlled, predictable manner. Notably, the trial demonstrated that trispecific targeting does not necessarily increase the risk of off-target toxicity, provided the antigens are restricted to the B-cell lineage. Consequently, this therapy could potentially be administered in an outpatient setting or at centers with less intensive monitoring capabilities than those currently required for commercial products.

Clinical Efficacy and Survival Outcomes in Lymphoma

The clinical efficacy of the trispecific CAR T cells was impressive, particularly in the lymphoma patient cohort. The overall response rate (ORR) across all B-cell malignancies was 50%. However, when focusing specifically on patients with lymphoma, the complete response (CR) rate reached a remarkable 83%. These results are particularly noteworthy given that many participants had relapsed or refractory disease that had failed multiple prior lines of therapy. Furthermore, the one-year overall survival rate was 61%, with several patients maintaining durable remissions. Interestingly, the study found that CAR T expansion did not directly correlate with the dose administered or the clinical response. Instead, the researchers identified that T-cell exhaustion in the initial apheresis cells strongly correlated with progressive disease. This finding suggests that the quality of the patient's own immune system prior to engineering is a critical determinant of success. Therefore, future strategies may need to focus on optimizing the health of T cells during the collection phase to ensure the best possible outcomes for all treated individuals.

Frequently Asked Questions

What is the primary benefit of targeting three antigens instead of one?

The primary benefit involves preventing antigen escape, which is a leading cause of relapse in traditional CAR T therapies. When a therapy targets only CD19, the tumor may stop expressing that protein to survive. By simultaneously targeting CD19, CD20, and CD22, the trispecific CAR T cells ensure that even if one marker is lost, the others remain active. This approach provides a much more comprehensive coverage of heterogeneous B-cell populations, significantly reducing the likelihood of tumor recurrence and improving long-term remission rates.

How does the seven-day vein-to-vein time change clinical practice?

A seven-day vein-to-vein time dramatically improves patient outcomes by reducing the waiting period for treatment. In many cases, patients with refractory malignancies have rapidly progressing disease that can become untreatable within weeks. Rapid point-of-care manufacturing allows clinicians to treat patients while they are still healthy enough to respond. Additionally, it eliminates the need for expensive bridging chemotherapy and the logistical risks of cryopreservation. This efficiency makes the therapy more accessible and practical for hospitals to implement as a standard procedure.

Why was the lack of severe neurotoxicity significant in this trial?

The absence of severe neurotoxicity and cytokine release syndrome is a major breakthrough because these side effects are often the limiting factors of CAR T therapy. Severe neurotoxicity can lead to significant morbidity and requires intensive care monitoring, which increases costs and limits the number of centers that can offer treatment. By maintaining a safe profile while achieving high efficacy, this trispecific therapy proves that advanced immunotherapy can be both powerful and manageable. This safety profile opens the door for treating a broader range of patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Vasu S et al. Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Blood Cancer Discov. 2026 Jul 14. doi: 10.1158/2643-3230.BCD-26-0186. PMID: 42446920.

Schneider D, Xiong Y, Wu D, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021;13(586):eabc6401. doi: 10.1126/scitranslmed.abc6401.

Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies: a phase 1 dose-escalation trial. Nat Med. 2020;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3.